Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 45 points (-0.3%) at 17,859 as of Wednesday, June 17, 2015, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,059 issues advancing vs. 1,922 declining with 184 unchanged. The Drugs industry currently sits up 0.3% versus the S&P 500, which is down 0.2%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 1.2%, and Valeant Pharmaceuticals International ( VRX), up 0.6%. On the negative front, top decliners within the industry include Alkermes ( ALKS), down 3.1%, Novo Nordisk A/S ( NVO), down 1.6% and Gilead ( GILD), down 0.8%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biomarin Pharmaceutical is up $1.72 (1.4%) to $122.82 on light volume. Thus far, 430,814 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $121.58-$122.97 after having opened the day at $121.80 as compared to the previous trading day's close of $121.10. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $19.5 billion and is part of the health care sector. Shares are up 34.9% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.